Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Connie Tat

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Autoimmunity|May 16, 2014
MicroRNAs in lupusHong Zan, Connie Tat, Paolo Casali
Nature Communications|February 9, 2017
Rad52 competes with Ku70/Ku86 for binding to S-region DSB ends to modulate antibody class-switch DNA recombinationHong Zan, Connie Tat, Zhifang Qiu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 14, 2014
Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responsesClayton A White, Egest J Pone, Tonika Lam, et al.
European Urology Oncology|July 2, 2024
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010Jose Antonio Karam, Robert Uzzo, Axel Bex, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Autoimmunity|May 16, 2014
MicroRNAs in lupusHong Zan, Connie Tat, Paolo Casali
Nature Communications|February 9, 2017
Rad52 competes with Ku70/Ku86 for binding to S-region DSB ends to modulate antibody class-switch DNA recombinationHong Zan, Connie Tat, Zhifang Qiu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 14, 2014
Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responsesClayton A White, Egest J Pone, Tonika Lam, et al.
European Urology Oncology|July 2, 2024
Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010Jose Antonio Karam, Robert Uzzo, Axel Bex, et al.
Pageof 1